Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study is to compare pharmacokinetics and safety profiles of single-administration of DA-5222 and co-administration of DA-5222-R1, DA-5222-R2 and DA-5222-R3 in healthy adult subjects in fed state
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Sequence A | Experimental |
| |
| Sequence B | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DA-5222 | Drug | single dose administration (DA-5222 one tablet once a day) |
|
| Measure | Description | Time Frame |
|---|---|---|
| AUCt | Area Under the Curve | pre-dose~48 hours post-dose |
| Cmax | Maximum Plasma Concentration | pre-dose~48 hours post-dose |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Bumin Hospital | Seoul | Gangseo-gu | 07590 | South Korea |
Not provided
DA-5222, DA-5222-R1, DA-5222-R2, DA-5222-R3
Not provided
Not provided
Not provided
Not provided
| DA-5222-R1 | Drug | single dose administration (DA-5222-R1 one tablet once a day) |
|
| DA-5222-R2 | Drug | single dose administration (DA-5222-R2 one tablet once a day) |
|
| DA-5222-R3 | Drug | single dose administration (DA-5222-R3 one tablet once a day) |
|